|
Match
|
Document |
Document Title |
|
|
6849602 |
Compositions for alleviating neuropathic pain with prosaposin receptor agonists
The invention provides a method of alleviating neuropathic pain in a subject by administering a neuropathic pain alleviating amount of prosaposin receptor agonist to the subject. The invention also...
|
|
|
6849593 |
Bifidogenic peptides
Pepetides having bifidogenic properties are obtainable by the process of adding proteases to cow'milk or human milk, followed by incubation, centrifugation, acidification, purification by reverse...
|
|
|
6849596 |
Regulatory/unfolding peptides of ezrin
This invention describes novel charged molecules which specifically bind to the Hepreceptor, a regulatory site which I have discovered in human ezrin. My invention is that when peptides or other...
|
|
|
6838433 |
IL-6 antagonist peptides
The present invention relates to IL-6 antagonist peptides, isolatable from a peptide library through the two-hybrids system by their ability to bind to the intracellular domain of gp130 and...
|
|
|
6838441 |
Albumin for treating meconium aspiration syndrome
The present invention provides a method of treating meconium aspiration syndrome, said method comprising administering to a subject in need of treatment a therapeutically effective amount of...
|
|
|
6838428 |
Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
Surfactant protein D (SP-D) is a 43-kDa member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. The SP-D gene was targeted...
|
|
|
6838438 |
Motilin Homologs
The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of...
|
|
|
6835382 |
Ii peptide therapeutics to enhance antigen presentation
Disclosed is a class of compounds referred to herein as effector compounds. Effector compounds are useful in connection with the modulation of an immune response. Modulation refers to the ability...
|
|
|
6828304 |
Peptides for treatment of cancer
This invention relates to novel antiproliferative and anti secrectory peptides that are inhibitory to vasoactive intestinal peptide receptor and are useful in the treatment of cancer. The invention...
|
|
|
6827937 |
HBV capsid-binding peptide immunogens
This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core...
|
|
|
6825178 |
Methods and products for treating pseudomonas infection
Methods and products for upregulating cystic fibrosis transmembrane conductance regulators are provided, including methods and products for the treatment of P. aeruginosa infection. The products...
|
|
|
6821950 |
Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors
The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G...
|
|
|
6818217 |
Immunoreactive peptides
The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with antibodies or T-cells in subjects having pre-clinical or...
|
|
|
6818617 |
EC-3, an inhibitor of α4β1 and α4β7 integrins
This invention relates to the identification, purification, and characterization of a novel heterodimeric disintegrin, EC-3, from Echis carinatus viper venom. EC-3 inhibits α4 integrins in an...
|
|
|
6815421 |
Polypeptides for use in ameliorating effects of aging in mammals
Method of ameliorating effects of aging in an animal, the method comprising administering to the animal an effective amount of a synthetic polypeptide comprising an amino acid sequence that has...
|
|
|
6806255 |
Compounds and methods for modulating adhesion molecule function
Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic...
|
|
|
6790447 |
Peptides for treatment of autoimmune diseases
The invention refers to peptides consisting of 7 to 20 amino acid residues with the sequence A-Leu-B-Ser-C-Thr-Ala-Ala-D, in which B and C are each an amino acid or amino acids and A and D are...
|
|
|
6790833 |
Antifungal and antibacterial agents
The present invention discloses peptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7. The peptides are between 8 and 20 amino acids in length and have a net positive...
|
|
|
6787141 |
Peptide having for fibrinogen fragment E activity, analogs, antibodies and uses thereof
Fibrin degradation products stimulate cell proliferation and angiogenesis. The present invention provides peptides, analogs, and antibodies which are useful in the modulation of binding fibrin...
|
|
|
6787517 |
Agent and methods for treating pain
Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent are disclosed. The agent...
|
|
|
6784155 |
Inhibitor and stimulator of stem cell proliferation and uses thereof
Disclosed and claimed are methods for the isolation and use of stem cell modulating factors for regulating stem cell cycle and for accelerating the post-chemotherapy peripheral blood cell recovery....
|
|
|
6780843 |
Sequence and method for genetic engineering of proteins with cell membrane translocating activity
The invention describes a membrane-translocating peptide sequence (MTS) which facilitates entry of polypeptides and proteins into cells. Also described is an isolated nucleotide sequence encoding...
|
|
|
6770626 |
Tissue remodeling
The invention concerns a method for the modulation of tissue-remodeling processes, by contacting the tissue to be remodeled with a compound comprising a sequence derived from certain regions of...
|
|
|
6759234 |
Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
The present invention provides therapeutic compositions and methods for treating disease conditions in humans associated with an antigen specific immune response by the human to an antigen such as...
|
|
|
6753313 |
Multimeric Apoa-I agonist compounds
The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a...
|
|
|
6750197 |
Activators of endothelial nitric oxide synthase
The regulatory peptides for constitutive nitric oxide synthase enzymes, and a peptide specific to inducible nitric oxide synthase, as well as derivatives of the peptides, homologous peptides,...
|
|
|
6750200 |
M2GlyR derived channel forming peptides
The present invention provides a family of peptides based upon the M2GlyR sequence. These peptides are derivatives of the M2GlyR sequence and can be modified at their ends to include a plurality of...
|
|
|
6743769 |
Antimicrobial peptides and derived metapeptides
The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition,...
|
|
|
6740638 |
Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any...
|
|
|
6737406 |
Cryptic peptides and method for their identification
The present invention relates to immunologically cryptic peptides; methods for their identification in individuals and populations and their use in diagnosis and therapy of pathological conditions...
|
|
|
6734166 |
Method of reducing aluminum levels in the central nervous system
A method of reducing aluminum concentrations in the central nervous system of a subject (e.g., a patient afflicted with Alzheimer's disease or at risk of developing Alzheimer's disease) comprises...
|
|
|
6730660 |
Peritoneal dialysis solutions with polypeptides
The present invention provides an improved dialysis solution. The improved dialysis solution provides for the use of specific polypeptides as an osmotic agent with an additional osmotic agent such...
|
|
|
6716817 |
Method of treatment of female infertility
A method of treating female infertility using a novel cetrorelix acetate lyophilizate is disclosed.
|
|
|
6716809 |
Mage-A3 peptides presented by HLA class molecules
The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides...
|
|
|
6716811 |
Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses
Novel compounds are provided that bind to G-CSFR. The novel compounds have a peptide chain approximately 6 to 40 amino acids in length that binds to G-CSFR. The compounds are useful as probes for...
|
|
|
6716810 |
Composition and method for regulation of body weight and associated conditions
Described are methods and compositions for regulating body weight and/or regulating the rate of weight gain or loss, and particularly, for treating or preventing obesity. Specifically, methods of...
|
|
|
6713449 |
E2F activity inhibitory compounds
E2F-inhibiting compounds are represented by the formula: R 1 —A—R 2 wherein A represents a peptide sequence comprising a partial amino acid sequence having at least 12 continuous residues in...
|
|
|
6699838 |
Antiangiogenic peptides
Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also...
|
|
|
6699833 |
Pharmaceutical formulations for sustained drug delivery
Sustained delivery formulations comprising a water-insoluble complex of a peptide and a carrier macromolecule are disclosed. The formulations of the invention allow for loading of high...
|
|
|
6696412 |
High purity lipopeptides, Lipopeptide micelles and processes for preparing same
The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential...
|
|
|
6696408 |
Contulakin-G, analogs thereof and uses therefor
The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr 10 -contulakin-G), and derivatives thereof, to a cDNA clone...
|
|
|
6696274 |
Ligand for enhancing oral and CNS delivery of biological agents
Provided herein is a novel and useful Ligand comprising a peptide comprising an amino acid sequence of SEQ. ID. NO.:6, an analog, a derivative, or a variant thereof, which increases the absorption...
|
|
|
6696061 |
Immunomodulatory peptides
A purified preparation of a peptide consisting essentially of an amino acid sequence identical to that of a segment of a naturally-occurring human protein, said segment being of 10 to 30 residues...
|
|
|
6686333 |
Inhibition of HIV replication using soluble Tat peptide analogs
Methods and compositions for inhibiting replication of HIV in a mammalian cell. The compositions can be a peptide, or a nucleic acids encoding a peptide, which inhibits transactivation of the HIV...
|
|
|
6685943 |
Fibronectin binding protein compositions and methods of use
Disclosed are antibodies that block the binding of fibronectin protein to fibronectin. Also disclosed are site specifically-mutated and truncated peptide epitopes derived from the fnbA and fnbB...
|
|
|
6682740 |
Peptides derived fram complement peptide C3a sequence and antiallergic compositions comprising them
Peptides corresponding partially or entirely to positions 50-77 of the sequence of the complement-derived peptide C3 a and analogs thereof are capable of inhibiting IgE-mediated triggering and/or...
|
|
|
6683048 |
Compounds and methods for stimulating gene expression and cellular differentiation
Modulating agents for inhibiting an interaction between α-catenin and β-catenin are provided. The modulating agents comprise one or more of: (a) a β-catenin HAV motif; (b) a peptide analogue or...
|
|
|
6680058 |
Compositions and methods for contraception in or sterilization of mammals
Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to induce sterility or long-term contraception in mammals. The peptides act directly on cell membranes, and...
|
|
|
6677116 |
Methods for treating cancer by modulating β-catenin mediated gene expression
Modulating agents for inhibiting β-catenin mediated gene expression are provided. The modulating agents comprise one or more of: (1) the peptide sequence LXXLL (SEQ ID NO:1); or (2) a peptide...
|
|
|
6673769 |
Lanthionine bridged peptides
Disclosed are lanthionine bridged peptides having the structure methods of their preparation and their use as pharmacologically active agents.
|